SYNBIOMATICA

Daily briefings

Editor’s Briefing: November 20, 2026

In Short. Bloomberg reported that Sanofi is considering a takeover of Insmed, a US biotech with two approved lung medicines. Celldex stopped work on barzolvolimab for eczema after a Phase 2 trial missed its main goal. A Bausch + Lomb eye drop for pain after laser surgery also missed its main goal. Revolution Medicines reported updated first-line results for daraxonrasib plus chemotherapy in metastatic pancreatic cancer.

Sanofi is reported to be considering a takeover of Insmed

SANOFI, a French drugmaker, is considering a takeover of Insmed, Bloomberg reported on Thursday, citing people familiar with the matter (Fierce Pharma, Reuters). Insmed is a US biotech whose approved medicines include Arikayce, an inhaled antibiotic for a lung infection caused by Mycobacterium avium complex, and Brinsupri (brensocatib), a pill for non-cystic fibrosis bronchiectasis, a disease in which the airways widen and thicken (FDA snapshot, Arikayce label).

Bloomberg said Sanofi is speaking with advisers as it studies a possible deal. Bloomberg's sources said talks are still under way, a deal could still be weeks away, and Sanofi might not make an offer. Sanofi said it does not comment on market rumors, according to Reuters. Insmed declined to comment, Fierce Pharma said. In October Sanofi's finance chief said the company had more interest in larger deals, Fierce Pharma reported.

Celldex stops barzolvolimab work in atopic dermatitis

ATOPIC dermatitis, also called eczema, is a chronic skin disease that causes itchy, inflamed skin. On Thursday Celldex reported Phase 2 results for barzolvolimab, an antibody designed to block the KIT receptor, a protein mast cells need to survive (announcement). The trial assigned 131 people, in equal groups, to 150 mg or 300 mg injections every four weeks after a 450 mg first dose, or to placebo, for 16 weeks.

The main goal was the percent change in a weekly itch score at week 16. That score fell by 29.2% on the 300 mg dose and by 19.5% on placebo (p=0.187), and by 16.2% on the 150 mg dose (p=0.651). Neither dose met the p=0.1 threshold. The company said skin-severity scores did not meaningfully differ from placebo and did not give those figures. It is stopping work in atopic dermatitis, still plans a 2027 application for chronic spontaneous urticaria, a disease of recurring hives, and did not describe unwanted-effect rates.

Bausch + Lomb's BL1332 misses its main goal in post-surgical eye pain

LASER surgery to correct nearsightedness, called photorefractive keratectomy, can leave the eye surface painful while it heals. On Thursday Bausch + Lomb reported Phase 2 results for BL1332, an eye drop designed to block TRPV1, a protein on nerve cells that helps transmit pain signals (announcement). The trial assigned 129 adults, in a 2 to 2 to 1 ratio, to a 0.30% drop, a 0.15% drop, or a comparison drop without the drug.

The study did not meet its main goal, a combined pain-intensity score over the first 24 hours. The difference versus the comparison drop was -11.5 for the 0.30% dose and -9.0 for the 0.15% dose, with negative numbers meaning less pain. The company said there were no treatment-related or serious unwanted effects and plans to discuss the results with the FDA.

Revolution Medicines updates first-line pancreatic cancer results for daraxonrasib plus chemotherapy

PANCREATIC adenocarcinoma is the most common form of pancreatic cancer and is often found after it has spread. On Thursday Revolution Medicines reported updated results from a Phase 1/2 first-treatment study of RASONQUE (daraxonrasib), a daily pill that blocks RAS growth-switch proteins, plus chemotherapy (announcement). The pill is already approved in the United States for adults with metastatic disease after at least one earlier drug treatment, or when combination chemotherapy cannot be used (FDA). The new analysis had no comparison group.

As of September 28, 61 people had received a 200 mg dose plus gemcitabine and nab-paclitaxel, with a median follow-up of 18.3 months. Tumors shrank in a confirmed way in 37 of 61 people (60.7%), including a complete disappearance in 5 of 61 (8.2%). Disease was at least stable in 55 of 61 (90.2%). The median time until the disease worsened was 12.8 months, and the estimated share alive at one year was 76.6%. The company did not report unwanted-effect rates. A Phase 3 trial, RASolute 303, is testing the combination as a first treatment. The findings were due Friday at a cancer meeting in Barcelona.

What to watch

By November 22 the FDA is due to decide on Capricor's deramiocel for Duchenne muscular dystrophy, an inherited muscle-wasting disease, and on Savara's inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare disease in which a protein-rich fluid builds up in the lungs. A decision on BridgeBio's BBP-418 for limb-girdle muscular dystrophy type 2I/R9, an inherited muscle-wasting disease, is due on November 27.

Sources

  1. Bloomberg: Sanofi is said to weigh takeover of US drugmaker Insmed
  2. Fierce Pharma: Facing down Dupixent cliff, Sanofi mulls buyout of Insmed
  3. Celldex: Phase 2 results for barzolvolimab in atopic dermatitis
  4. Bausch + Lomb: Phase 2 findings for BL1332 in post-surgical ocular pain
  5. Revolution Medicines: updated Phase 1/2 data for daraxonrasib in first-line panc